BioCentury | Aug 22, 2020
Management Tracks

Qiagen chairman steps down, plus changes at Sanifit and Xeris

...Xeris Pharmaceuticals Inc. (NASDAQ:XERS) has promoted COO John Shannon to president and COO. Elizabeth S. Eaton Qiagen N.V. Laboratoris Sanifit S.L. Xeris Pharmaceuticals Inc....
BioCentury | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

...to peanuts after accidental exposure in patients aged 4-17. Xeris wins FDA approval for Gvoke Xeris Pharmaceuticals Inc....
...the sale of a second Sackler company, Mundipharma International Ltd. (Dublin, Ireland). BioCentury Staff GlaxoSmithKline plc Aimmune Therapeutics Inc. Xeris Pharmaceuticals Inc. Purdue...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:OVID) 2/20/19 $28.0 $77.3 $71.6 -7% Achaogen Inc. (Pink:AKAOQ) (A) 2/15/19 $15.0 NA $1.3 NA Xeris Pharmaceuticals Inc....
BioCentury | Apr 16, 2019
Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

...Pharmaceuticals Inc. (Montreal, Quebec) named Paul Edick as chairman. He is chairman and CEO of Xeris Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Finance

Pause for politics

...NASDAQ:AVRO) 6/20/18 $114.7 $454.8 $672.6 48% Magenta Therapeutics Inc. (NASDAQ:MGTA) 6/20/18 $100.0 $515.6 $459.2 -11% Xeris Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Clinical News

Xeris' G-Pen increases plasma glucose in Phase III pediatric hypoglycemia

...presented at the American Diabetes Association meeting in Orlando. Xeris’ G-Pen contains stable liquid glucagon. Xeris Pharmaceuticals Inc....
...to 30 minutes; pharmacokinetics Status: Phase III data Milestone: NA Jaime De Leon G-Pen, glucagon injection American Diabetes Association Xeris Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Clinical News

Xeris' G-Pen similar to standard kit in Phase III hypoglycemia

...all patients from insulin-induced hypoglycemia without other rescue therapy. Xeris’ G-Pen contains stable liquid glucagon. Xeris Pharmaceuticals Inc....
...pharmacokinetics and hypoglycemia symptoms Status: Phase III data Milestone: NA Jaime De Leon G-Pen, glucagon injection American Diabetes Association Xeris Pharmaceuticals Inc....
BioCentury | Jun 22, 2018
Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

...a Phase Ib/II study of lead candidate KZR-616 to treat lupus and lupus nephritis. Finally, Xeris Pharmaceuticals Inc....
...price valued Xeris at $296 million. The company had planned to sell 5 million shares. Xeris...
...NASDAQ:KZR), South San Francisco, Calif. Xeris Pharmaceuticals Inc. (NASDAQ:XERS), Austin, Texas Paul Bonanos Aptinyx Inc. Avrobio Inc. Kezar Life Sciences Magenta Therapeutics Inc. Xeris Pharmaceuticals Inc....
BioCentury | Jun 21, 2018
Financial News

Four companies in IPO quintet post first-day gains

...to treat lupus and lupus nephritis. Finally, Xeris Pharmaceuticals Inc. (NASDAQ:XERS) gained $2.75 (18%) to $17.75 Thursday. Xeris...
...price valued Xeris at $296 million. The company had planned to sell 5 million shares. Xeris...
...delivers glucagon via an auto-injector to treat severe hypoglycemia. Paul Bonanos Aptinyx Inc. Avrobio Inc. Kezar Life Sciences Magenta Therapeutics Inc. Xeris Pharmaceuticals Inc....
BioCentury | Feb 1, 2016
Finance

Unfinished business

...play Syros Pharmaceuticals Inc. , DNA synthesis company Twist Bioscience Corp. and drug delivery play Xeris Pharmaceuticals Inc....
Items per page:
1 - 10 of 22
BioCentury | Aug 22, 2020
Management Tracks

Qiagen chairman steps down, plus changes at Sanifit and Xeris

...Xeris Pharmaceuticals Inc. (NASDAQ:XERS) has promoted COO John Shannon to president and COO. Elizabeth S. Eaton Qiagen N.V. Laboratoris Sanifit S.L. Xeris Pharmaceuticals Inc....
BioCentury | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

...to peanuts after accidental exposure in patients aged 4-17. Xeris wins FDA approval for Gvoke Xeris Pharmaceuticals Inc....
...the sale of a second Sackler company, Mundipharma International Ltd. (Dublin, Ireland). BioCentury Staff GlaxoSmithKline plc Aimmune Therapeutics Inc. Xeris Pharmaceuticals Inc. Purdue...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:OVID) 2/20/19 $28.0 $77.3 $71.6 -7% Achaogen Inc. (Pink:AKAOQ) (A) 2/15/19 $15.0 NA $1.3 NA Xeris Pharmaceuticals Inc....
BioCentury | Apr 16, 2019
Company News

Management tracks: Ginkgo Bioworks, KSQ, Milestone, Cerebral

...Pharmaceuticals Inc. (Montreal, Quebec) named Paul Edick as chairman. He is chairman and CEO of Xeris Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Finance

Pause for politics

...NASDAQ:AVRO) 6/20/18 $114.7 $454.8 $672.6 48% Magenta Therapeutics Inc. (NASDAQ:MGTA) 6/20/18 $100.0 $515.6 $459.2 -11% Xeris Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Clinical News

Xeris' G-Pen increases plasma glucose in Phase III pediatric hypoglycemia

...presented at the American Diabetes Association meeting in Orlando. Xeris’ G-Pen contains stable liquid glucagon. Xeris Pharmaceuticals Inc....
...to 30 minutes; pharmacokinetics Status: Phase III data Milestone: NA Jaime De Leon G-Pen, glucagon injection American Diabetes Association Xeris Pharmaceuticals Inc....
BioCentury | Jul 13, 2018
Clinical News

Xeris' G-Pen similar to standard kit in Phase III hypoglycemia

...all patients from insulin-induced hypoglycemia without other rescue therapy. Xeris’ G-Pen contains stable liquid glucagon. Xeris Pharmaceuticals Inc....
...pharmacokinetics and hypoglycemia symptoms Status: Phase III data Milestone: NA Jaime De Leon G-Pen, glucagon injection American Diabetes Association Xeris Pharmaceuticals Inc....
BioCentury | Jun 22, 2018
Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

...a Phase Ib/II study of lead candidate KZR-616 to treat lupus and lupus nephritis. Finally, Xeris Pharmaceuticals Inc....
...price valued Xeris at $296 million. The company had planned to sell 5 million shares. Xeris...
...NASDAQ:KZR), South San Francisco, Calif. Xeris Pharmaceuticals Inc. (NASDAQ:XERS), Austin, Texas Paul Bonanos Aptinyx Inc. Avrobio Inc. Kezar Life Sciences Magenta Therapeutics Inc. Xeris Pharmaceuticals Inc....
BioCentury | Jun 21, 2018
Financial News

Four companies in IPO quintet post first-day gains

...to treat lupus and lupus nephritis. Finally, Xeris Pharmaceuticals Inc. (NASDAQ:XERS) gained $2.75 (18%) to $17.75 Thursday. Xeris...
...price valued Xeris at $296 million. The company had planned to sell 5 million shares. Xeris...
...delivers glucagon via an auto-injector to treat severe hypoglycemia. Paul Bonanos Aptinyx Inc. Avrobio Inc. Kezar Life Sciences Magenta Therapeutics Inc. Xeris Pharmaceuticals Inc....
BioCentury | Feb 1, 2016
Finance

Unfinished business

...play Syros Pharmaceuticals Inc. , DNA synthesis company Twist Bioscience Corp. and drug delivery play Xeris Pharmaceuticals Inc....
Items per page:
1 - 10 of 22